# China NMPA Drug Inspection - Bozhou Haomen Traditional Chinese Medicine Pieces Co., Ltd. - Typha pollen

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/bozhou-haomen-traditional-chinese-medicine-pieces-co-ltd/acb70231-7610-4cd2-a72e-f3ecc2276d2b/
Source feed: China

> China NMPA drug inspection for Bozhou Haomen Traditional Chinese Medicine Pieces Co., Ltd. published June 15, 2018. Drug: Typha pollen. The Henan Provincial Food and Drug Administration announced on June 15, 2018, the discovery of four batches of substanda

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from the Henan Provincial Food and Drug Administration regarding four batches of substandard drugs (Issue No. 6, 2018)
- Company Name: Bozhou Haomen Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2018-06-15
- Drug Name: Typha pollen
- Inspection Finding: Total ash, leachate, and auramine are all substandard.
- Action Taken: Necessary risk control measures such as sealing, seizing, and suspending sales will be implemented, and the units that source the samples will be investigated and dealt with in accordance with the law.
- Summary: The Henan Provincial Food and Drug Administration announced on June 15, 2018, the discovery of four batches of substandard traditional Chinese medicine products from four different manufacturers. Inspections, conducted by municipal drug inspection institutes, revealed significant quality control issues. Anhui Jisongtang Traditional Chinese Medicine Pieces Co., Ltd. produced "Earthworm" (batch 20161001), which failed appearance standards. Bozhou Haomen Traditional Chinese Medicine Pieces Co., Ltd.'s "Typha orientalis" (batch 150401) was found to be substandard in total ash, extractives, and auramine content. Furthermore, Tianma (Anhui) Traditional Chinese Medicine Pieces Technology Co., Ltd.'s "Stir-fried Atractylodes lancea" (batch 170501) had unacceptable moisture and other quality deficiencies, while Anhui Zehua Traditional Chinese Medicine Pieces Co., Ltd.'s "Stir-fried Atractylodes lancea" (batch 160801) showed substandard active content. These violations were assessed against the Henan Province Traditional Chinese Medicine Pieces Processing Standard (2005 Edition) and the Chinese Pharmacopoeia (2010 and 2015 editions). In response, the Henan Provincial Food and Drug Administration has directed local regulatory bodies to implement immediate risk control measures, including the sealing, seizing, and suspending sales of the affected products. Legal investigations and penalties for the responsible suppliers are also mandated. This action underscores the provincial administration's commitment to upholding drug quality and safety standards.

Company: https://www.globalkeysolutions.net/companies/bozhou-haomen-traditional-chinese-medicine-pieces-co-ltd/df9113d5-2c12-4f64-ab68-0c9827cdd2b3/